News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 28

    Sep

    22

  • KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

  • 01

    Sep

    22

  • KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  • 11

    Aug

    22

  • KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates

  • 09

    Aug

    22

  • KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

  • 04

    Aug

    22

  • KemPharm to Report Second Quarter 2022 Financial Results

  • 02

    Aug

    22

  • KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference

  • 26

    Jul

    22

  • KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting

  • 01

    Jun

    22

  • KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion

  • 16

    May

    22

  • KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

  • 12

    May

    22

  • KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates

  • 11

    May

    22

  • KemPharm to Present at Multiple Upcoming Investor Conferences

  • 05

    May

    22

  • KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)